Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Preoperative Chemoradiotherapy for GEJ Adenocarcinoma
NCT04061928Phase 2Unknown
- Sponsor
- Peking University
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
Phase 2, open-label, single-arm trial of sugemalimab in gastroesophageal junction adenocarcinoma, sponsored by Peking University. Primary endpoint: Tumor Regression Grading. Status: unknown.
02
Drugs
sugemalimab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04061928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061928.